

Anti-FOLR1-DM4(Dar3.4)[Mirvetuximab soravtansine]

Product Information


Product Name	Anti-FOLR1-DM4(Dar3.4)[Mirvetuximab soravtansine]
Storage temp.	Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.
Catalog# / Size	GM-87844AB-100 / 100 µg GM-87844AB-1mg / 1 mg

Antibody Information


Expression System	CHO
Purity	> 95% as determined by SDS-PAGE
Aggregation	< 5% as determined by SEC-HPLC
Drug-to-Antibody Ratio (DAR)	3.0-4.0
Endotoxin	<1EU/mg
Sterility	0.22 µm Filtered
Target	FOLR1
Clone	Mirvetuximab soravtansine
Alternative Names	FBP, FOLR, FRalpha, NCFTD
Source/Isotype	Monoclonal Human IgG1, kappa
Application	Positive control of Cytotoxicity Assay
Description	Mirvetuximab soravtansine-gynx (MIRV) is a first-in-class antibody-drug conjugate targeting folate receptor α (FR α), which has been approved in the United States for the treatment of platinum-resistant ovarian cancer. Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate (ADC) composed of the cytotoxic maytansinoid DM4, covalently linked to the humanized monoclonal antibody M9346A. Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). It demonstrates antiproliferative effects by inhibiting growth and enhancing DNA damage.
Formulation	Phosphate-buffered solution, pH 7.2.

Version:3.2

SDS-PAGE




SEC-HPLC



The purity of this product is greater than 95% verified by SEC-HPLC.

UV-Vis



The drug-to-antibody ratio (DAR) of this product is 3.42.